Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.

[1]  C. Eika.  The platelet aggregating effect of eight commercial heparins. , 2009, Scandinavian journal of haematology.

[2]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[3]  Organisation to Assess Strategies for Ischemic Syndromes Investigators.  Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial , 1999, The Lancet.

[4]  S. Goto,et al.  Enhanced shear-induced platelet aggregation in acute myocardial infarction. , 1999, Circulation.

[5]  C J Knight,et al.  Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis. , 1998, European heart journal.

[6]  E. Vicaut,et al.  Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. , 1998, Circulation.

[7]  E. Antman,et al.  Low-molecular-weight heparins: an intriguing new twist with profound implications. , 1998, Circulation.

[8]  P Théroux,et al.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.

[9]  L. Rabbani,et al.  Percutaneous interventions alter the hemostatic profile of patients with unstable versus stable angina. , 1997, Journal of the American College of Cardiology.

[10]  A. Folsom,et al.  Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 1997, Circulation.

[11]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .

[12]  W. Klein,et al.  Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) , 1997, Circulation.

[13]  E. Vicaut,et al.  Fibrinogen after coronary angioplasty as a risk factor for restenosis. , 1995, Circulation.

[14]  D. Waters,et al.  Reactivation of unstable angina after the discontinuation of heparin. , 1992, The New England journal of medicine.

[15]  J. Moake,et al.  von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. , 1991, The Journal of clinical investigation.

[16]  P. Fay,et al.  von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. , 1991, The Journal of biological chemistry.

[17]  M. Roncaglioni,et al.  Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. , 1990, Journal of the American College of Cardiology.

[18]  G. Montalescot,et al.  Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep. , 1990, Circulation.

[19]  D. Hoppensteadt,et al.  Biochemical and Pharmacologic Inequivalence of Low Molecular Weight Heparins , 1989, Annals of the New York Academy of Sciences.

[20]  J. Westwick,et al.  Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. , 1986, Thrombosis Research.

[21]  C. Forbes,et al.  The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. , 1973, Clinical science and molecular medicine.

[22]  M. Keltai,et al.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). , 1999, European heart journal.

[23]  A. Mattioli,et al.  Organization to Assess Strategies for Ischemic Syndrome (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on preventing death, myocardial infarction, refractory angina and revascularization procedures in patients with acute myocardial ischemia without ST eleva , 1999 .

[24]  Z. Ruggeri,et al.  von Willebrand factor as a target for antithrombotic intervention. , 1992, Circulation.

[25]  R. Rosenberg,et al.  Effect of heparin and heparin fractions on platelet aggregation. , 1980, The Journal of clinical investigation.